In Labiotech’s deep dive on emerging prostate cancer treatments, the standout innovation comes from Jonas Båtelson, CEO of Curacell, explains that CC‑38 is designed specifically to overcome the immunosuppressive “cold tumor” environment that makes these cancers resistant to immunotherapy. By reviving exhausted T cells and restoring their ability to recognise and attack tumors, CuraCell’s platform aims to turn cold tumors hot and unlock responses where other immunotherapies fail.

The article highlights CuraCell’s ongoing Phase I/IIa trial in Frankfurt and underscores Jonas’s central message: the company has cracked a key challenge in solid‑tumor immunotherapy — revitalising naturally occurring T cells so they can persist, function, and kill cancer cells inside highly suppressive tumor microenvironments.

Read the full article here.